Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design.

@article{Karrison2012EstimationOP,
  title={Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design.},
  author={Theodore G. Karrison and Mark J. Ratain and Walter M. Stadler and Gary L. Rosner},
  journal={The American statistician},
  year={2012},
  volume={66 3},
  pages={155-162}
}
The randomized discontinuation trial (RDT) design is an enrichment-type design that has been used in a variety of diseases to evaluate the efficacy of new treatments. The RDT design seeks to select a more homogeneous group of patients, consisting of those who are more likely to show a treatment benefit if one exists. In oncology, the RDT design has been applied to evaluate the effects of cytostatic agents, that is, drugs that act primarily by slowing tumor growth rather than shrinking tumors… CONTINUE READING